Font Size: A+AA-
EN
CN
Online Message
Contact Information
One of telephone, mobile phone number, e-mail is required
Contact
Tel
Mobile phone
Email
QQ
WeChat Account
Message
Other additions
Verification code
Leave a message now Refill

Breaking News of C&O Pharmaceutical Technology

Views：

1.Aulimodi raw materials and tablets received clinical approval from the NMPA on October 18, 2016.

2.Omarigliptin hydrochloride raw materials and tablets received clinical approval from the NMPA on January 16, 2017.

203新澳门原料网站

Return List Previous：Shionogi new drug for influenza - Baloxavir (disclosed Phase III clinical trial data) Next：Medical insurance for Flumarin®
Top
About Us
About Us Development History Company Honor
Business Scope
Market Sales Technology Development Manufacture Center
Products
Antibiotics Digestive System Medication Cardiovascular and Cerebrovascular Medication Bone and Muscle Medication Dermatological Medication Respiratory System Medication Nervous System Medication medical device
News Release
Company News Notice
Contact Us
  • Official WeChat account Official WeChat account
  • Mobile pageMobile page
  • Service Tel0755-2552 7000
  • Business Tel0755-2552 7386
Message
LinksSite MapPrivacy Policy
Copyright @ 2022 C&O Pharmaceutical Technology (Holdings) Limited. All Rights Reserved.SICPB No. 05064170-1